热门资讯> 正文
IGM Biosciences宣布重新调整赛诺菲合作重点
2024-04-17 20:48
- IGM Biosciences (NASDAQ:IGMS) Wednesday reported that the company’s exclusive collaboration agreement with Sanofi (NASDAQ:SNY) to create and develop IgM agonist antibodies, will now focus exclusively on immunology/inflammation targets.
- IGM will retain global rights to its proprietary technology related to the oncology targets nominated by Sanofi under the collaboration.
- IGMS +6.96% premarket to $9.84.
- Source: Press Release
More on IGM Biosciences
- IGM Biosciences: Imvotamab Data 2nd Half Of 2024 With Other Inflection Points
- IGM Biosciences GAAP EPS of -$1.01 beats by $0.08, revenue of $0.7M misses by $0.07M
- RBC Capital upgrades IGM Biosciences to outperform
- Seeking Alpha’s Quant Rating on IGM Biosciences
- Historical earnings data for IGM Biosciences
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
